{"name":"AAVantgarde Bio Srl","slug":"aavantgarde-bio-srl","ticker":"","exchange":"","domain":"aavantgardebiosrl.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"AAVB-039","genericName":"AAVB-039","slug":"aavb-039","indication":"Other","status":"phase_1"},{"name":"AAVB-081","genericName":"AAVB-081","slug":"aavb-081","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AAVB-039","genericName":"AAVB-039","slug":"aavb-039","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"AAVB-081","genericName":"AAVB-081","slug":"aavb-081","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxQWDVVT0I3X1p5NmhLaFpnNkMyMzEtX3pYb3RQd25VamMzbnlwVWFyTFFvVk9NaHhrY0tDSzFzQy1xaGpJdmxmdWJ6TW9EUjdPZFNWODNremFrZjUxX2NxZWpFMVIza2JVUFdvWXExMTV4MXBHY2REeUN4bmtRSmhYSy0yWVcybHZUaWNESGFNc042LWhHcTd4N3E1RFZnOFFWU0xIT1Q5SFMwTGhNRk9tay00MlRzcjdHLUFBamJNSXZmTzV2V1RxekhqU3poSl9F?oc=5","date":"2026-02-25","type":"regulatory","source":"BioCentury","summary":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision - BioCentury","headline":"Rare disease spotlight: Stargardt’s first approval in sight as next-gen aims to restore vision","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNX3B2bzBNT3hINHFtTXRKVW1EVFVjUFo1OXYtdTJxQWZUNEJ4OC1tRW12cVRnYUJjRkRoYVZZUjdobnB4RWdQSXktN3V0ZE14b2RRYmxCUGRfckFxMzFVcXQ1R1MwNjNqWENKc3QtdUIzVkhQaDA3cjdEcTI1VXNiamRERDJZSXc2RWpnRTBFRmxXMUFiNGNmOFlKZmNNV1RWY2dFWS1uSTY0RkNuemxIcDY1RnJtRUtxRUQ5aDN5TFhhYWpGa3JNTTM4QVYta0tSZ2hLWmhhaFRXVFBTdTNONzN2MA?oc=5","date":"2026-02-19","type":"pipeline","source":"Barchart.com","summary":"Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - Barchart.com","headline":"Stargardt Disease Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQQ0lKbllzUko5aG93VVlFcVczRWh1V2ZIN19JWExVZVlGT25qaEY2dHlSbmF1djNHdjRDZmE1OVJad0U4TzhsUnZFWW9QN2tXSjdaSjV6SlZ5dlYxcEhzbjBhaThUbDZZLXFuZ0o0aHFIbmVuTUtBX0V1NEtKSWNYZlVLZFZsdXI0OE9UdFRmMNIBlAFBVV95cUxNUW14ajc1bk1ZaDRId2VGNFlJdEJWeWkyMEVjbm1jX1lzamY5ZFIxME8zOTR0RTRNY3dqZHBmR1lqWFBMRUFjMXpIZnh1d0R5VjlWMWNsdmNlMWVkT0I1RXJvS3FxN3JvZkNPcE9Fb0ZabHFVQUVta0V1T0dYN0Z6anowVTFVSW1rX081M190RFFmNDBn?oc=5","date":"2025-12-09","type":"deal","source":"Express Pharma","summary":"Pharma sector records higher deal value in November 2025 - Express Pharma","headline":"Pharma sector records higher deal value in November 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQVmh3MVNIODZLcFh4Q1YzUGRZc2tmam5CUnFUdVhiM0dhWFlpcW11N2JWMVhFQ3pZekJwODF0RkdkOGNCSjd6bUwwdGMtWkpoSS1ZZ3N3N0dkekhibFUwNFR3b3lORmlEZ3EzbktsZlJEWHN6UkFhWWh2cmNNdVhiR09iR2toVUY0Mm0yc2k3TEIyUTNwc1VLclZrWks4TzJMc0RaNnYyMEhuRXhkblhwakd4R1ExcEhEOXdocXFBdU1OZ0k?oc=5","date":"2025-11-03","type":"trial","source":"Fierce Biotech","summary":"Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials - Fierce Biotech","headline":"Italian biotech AAVantgarde adds $141M series B to fund retinal disease gene therapy trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiakFVX3lxTE5xT183ZlhiRUlEV3NwS2duenhuN2paSDVuUk8tVUlyb1VESU82YWtib2lSMHJMaXdwVWFCZFQ2Ul91eGVPci1SSlVLTTNwNjQyai1GUXV0MzVnZFdpS3NVRGpoWk1vX3Q1Smc?oc=5","date":"2025-11-03","type":"pipeline","source":"Labiotech.eu","summary":"AAVantgarde closes $141 million series B round to tackle inherited eye diseases - Labiotech.eu","headline":"AAVantgarde closes $141 million series B round to tackle inherited eye diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNNjhsM01xWTRlMVJRXzJyUUl4THR4bHRSdWVBdHB6UmwwM0tVWW82WWczWUJnenM0S0I2UlN1YmNsWkotdXNyMWtweHhpeVVLRGZ4bXpoYUhwamtqXzdIMXpXamJ5X29kRDJqMFFpQTR1cGxybEtBSEhrTFk2NU5XcGNsS1RHNXgzeU5KdlNpd1JoMEdkTXFXaEtMRm83V2hwaFludDAzZmgzXzduQ1BiVE8ta2JMN2JZaHNhVTNOWm00V0JISmNv?oc=5","date":"2025-07-16","type":"trial","source":"BioWorld News","summary":"Aavantgarde Bio cleared to begin clinical study of Stargardt disease gene therapy in US - BioWorld News","headline":"Aavantgarde Bio cleared to begin clinical study of Stargardt disease gene therapy in US","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}